Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
60–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Be of non-child bearing potential
Diagnosis of dry AMD including uni- or multi-focal geographic atrophy without foveal involvement
BCVA of 20/50 or better in the study eye
You may not be if
Evidence of ocular disease other than advanced AMD or GA in the study eye
History or diagnosis of exudative (wet) AMD, with subretinal or choroidal neovascular lesions in the study eye
Presence of disease or condition that might compromise the cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, central nervous immune, or gastrointestinal system
Requires ocular or systemic medications that are known to be toxic to the lens, retina or optic nerve
Clareo Health | Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
